Back to List View Graph View

Oxaliplatin

Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of gastrointestinal malignancies, especially colorectal and gastric cancers.

Where the papers sit

22 papers from the last 6 months study oxaliplatin directly · updated from PubMed 10 Nov 2026

Those 22 are all about one subject.

  • Cancer Chemotherapy Optimization

    Oxaliplatin therapy is being optimized through sensitizers, targeted delivery and immune-activating formulations, while clinical studies test regimen selection in gastric, colorectal and pancreatic cancer. Resistance work centers on HDAC4/TUG1, ARHGAP29, ATM/ATR-mediated repair, methylmalonic acid and sphingomyelin synthases. Nanoparticles, extracellular vesicles and biomimetic carriers aim to improve tumor exposure and reduce neurotoxicity. SOX, HIPEC, genomic profiling, organoid co-culture and nucleolar-stress signatures are extending treatment toward personalization, but efficacy remains context-dependent.

    22 papers

NEW DIRECTION

Oxaliplatin is studied as a cause of chemotherapy-associated cognitive impairment

The rat model of oxaliplatin-induced chemobrain studied thymol nanoparticles as a neuroprotective treatment rather than as an anticancer sensitizer. Oxaliplatin was found to impair cognition and produce histological and biochemical changes involving Nrf2/HO-1, endoplasmic-reticulum stress, and NLRP3 inflammasome signaling; thymol, particularly in nanoparticle formulations, ameliorated these effects. This extends oxaliplatin’s role in the set from an antitumor drug and resistance target to a cause of treatment-related neurological injury requiring its own therapeutic mitigation 42202464May.

NEW DIRECTION

Oxaliplatin is documented as a potential sexual-exposure hazard during chemotherapy

The subject of the rectal-cancer case report is oxaliplatin detected in vaginal secretions during FOLFOX treatment, rather than oxaliplatin as an antitumor agent, resistance determinant, delivery cargo, or treatment component. Urine contained detectable oxaliplatin for up to three days after chemotherapy, while polysorb vaginal swabs detected it on day one at approximately the limit of detection, with an estimated maximum of 2.5 ng per swab. This extends oxaliplatin research into survivorship safety and sexual-exposure assessment, creating a practical basis for counseling and exposure-risk evaluation during treatment 42855709Oct.

oxaliplatin chemical structure

Papers

The 22 papers from the last 6 months that study oxaliplatin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Cancer Chemotherapy Optimization (22)
  1. NaB-induced inhibition of HDAC4 and TUG1: a novel strategy for reversing oxaliplatin resistance in colorectal cancer. BMC cancer · 2 Nov 2026 PMID 42972541
  2. γ-T3 Increases the Sensitization of Gastric Cancer Cells to OXA by a Regulation of ARHGAP29. Journal of biochemical and molecular toxicology · 30 Oct 2026 PMID 42960555
  3. Sporoderm-Removed Particles Enhance Oxaliplatin Immunochemotherapy against Colorectal Cancer and Mitigate Neurotoxicity via Dual-Directional PINK1/Parkin Mitophagy. ACS applied materials & interfaces · 22 Oct 2026 PMID 42904478
  4. Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer. ACS macro letters · 20 Oct 2026 PMID 42899725
  5. Assessing sexual exposure to oxaliplatin in vaginal secretions during FOLFOX chemotherapy: a case report. Journal of medical case reports · 9 Oct 2026 PMID 42855709
  6. Methylmalonic Acid Induces Oxaliplatin Resistance Through Promoting DNA Damage Repair via the ATM/ATR Pathway in Gastric Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 7 Oct 2026 PMID 42839733
  7. Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy. Drug delivery · 22 Sept 2026 PMID 42771518
  8. Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
  9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience. Radiology and oncology · 7 Sept 2026 PMID 42704034
  10. An immune-activated co-culture model of patient-derived gastric cancer organoids and peripheral blood mononuclear cells for personalized chemotherapy screening. Acta biomaterialia · 30 Aug 2026 PMID 42669342
  11. Improved anti-tumour immune response of RBC-camouflaged oxaliplatin-zinc oxide albumin nanoparticles triggering robust activity in colorectal cancer cells. International journal of biological macromolecules · 27 Aug 2026 PMID 42660242
  12. Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600610
  13. Electrostatically engineered fucoidan-coated liposomal oxaliplatin: In silico, 2D 3D, in vivo pharmacokinetic evaluations for colorectal cancer management. International journal of biological macromolecules · 13 Aug 2026 PMID 42595156
  14. SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
  15. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
  16. A nucleolar stress gene signature enables quantitative scoring across multi-omics contexts. Communications biology · 29 Jun 2026 PMID 42373768
  17. Biomimetic adhesive hydrogel microcarriers for gas therapy and chemotherapy of gastric cancer. Acta biomaterialia · 12 Jun 2026 PMID 42285389
  18. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
  19. Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. ACS nano · 1 Jun 2026 PMID 42225301
  20. RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 May 2026 PMID 42217457
  21. Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
  22. Artesunate overcomes oxaliplatin resistance in colorectal cancer by inducing ferroptosis through inhibition of the CDK5/Nrf2/GPX4 pathway. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42178429

By study type

Clinical trials (2)
  1. Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600610
  2. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood advances · 10 Jun 2026 PMID 42269085
Observational studies and case reports (2)
  1. Assessing sexual exposure to oxaliplatin in vaginal secretions during FOLFOX chemotherapy: a case report. Journal of medical case reports · 9 Oct 2026 PMID 42855709
  2. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single-institution experience. Radiology and oncology · 7 Sept 2026 PMID 42704034
Human data, design not indexed (1)
  1. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 3 Aug 2026 PMID 42546248
Preclinical: animal, cell and lab studies (15)
  1. NaB-induced inhibition of HDAC4 and TUG1: a novel strategy for reversing oxaliplatin resistance in colorectal cancer. BMC cancer · 2 Nov 2026 PMID 42972541
  2. γ-T3 Increases the Sensitization of Gastric Cancer Cells to OXA by a Regulation of ARHGAP29. Journal of biochemical and molecular toxicology · 30 Oct 2026 PMID 42960555
  3. Sporoderm-Removed Particles Enhance Oxaliplatin Immunochemotherapy against Colorectal Cancer and Mitigate Neurotoxicity via Dual-Directional PINK1/Parkin Mitophagy. ACS applied materials & interfaces · 22 Oct 2026 PMID 42904478
  4. Dual-Targeting Nanoplatform Integrating Metabolic Glycan Labeling and Bioorthogonal Chemistry for Precise Delivery of Oxaliplatin to PSMA-Positive Prostate Cancer. ACS macro letters · 20 Oct 2026 PMID 42899725
  5. Methylmalonic Acid Induces Oxaliplatin Resistance Through Promoting DNA Damage Repair via the ATM/ATR Pathway in Gastric Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 7 Oct 2026 PMID 42839733
  6. Bioengineered extracellular vesicles integrating anti-EphA2 recognition and oxaliplatin delivery for pancreatic cancer therapy. Drug delivery · 22 Sept 2026 PMID 42771518
  7. Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
  8. An immune-activated co-culture model of patient-derived gastric cancer organoids and peripheral blood mononuclear cells for personalized chemotherapy screening. Acta biomaterialia · 30 Aug 2026 PMID 42669342
  9. Improved anti-tumour immune response of RBC-camouflaged oxaliplatin-zinc oxide albumin nanoparticles triggering robust activity in colorectal cancer cells. International journal of biological macromolecules · 27 Aug 2026 PMID 42660242
  10. Electrostatically engineered fucoidan-coated liposomal oxaliplatin: In silico, 2D 3D, in vivo pharmacokinetic evaluations for colorectal cancer management. International journal of biological macromolecules · 13 Aug 2026 PMID 42595156
  11. SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
  12. Biomimetic adhesive hydrogel microcarriers for gas therapy and chemotherapy of gastric cancer. Acta biomaterialia · 12 Jun 2026 PMID 42285389
  13. RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 May 2026 PMID 42217457
  14. Thymol nanoparticles ameliorate oxaliplatin-induced cognitive impairment via modulation of Nrf2/HO-1, endoplasmic reticulum stress, and NLRP3 inflammasome signaling in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 May 2026 PMID 42202464
  15. Artesunate overcomes oxaliplatin resistance in colorectal cancer by inducing ferroptosis through inhibition of the CDK5/Nrf2/GPX4 pathway. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42178429
Unclassified: not yet indexed with MeSH (2)
  1. A nucleolar stress gene signature enables quantitative scoring across multi-omics contexts. Communications biology · 29 Jun 2026 PMID 42373768
  2. Localized Depletion of Macrophages by Abdominal Cavity Retention Nanoparticles as a Potential Therapy for Peritoneal Metastasis. ACS nano · 1 Jun 2026 PMID 42225301